# A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD

> **NCT06359899** · PHASE3 · UNKNOWN · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** AK0901 capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06359899
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05
- **Primary completion:** 2024-09
- **Final completion:** 2024-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06359899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06359899, "A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06359899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*